264 related articles for article (PubMed ID: 27669228)
1. Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry.
Laakmann E; Witzel I; Scriba V; Grzyska U; Zu Eulenburg C; Burchardi N; Hesse T; Würschmidt F; Fehm T; Möbus V; von Minckwitz G; Loibl S; Park-Simon TW; Mueller V
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669228
[TBL] [Abstract][Full Text] [Related]
2. Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea.
Jang G; Lee SS; Ahn JH; Jung KH; Lee H; Gong G; Kim HH; Ahn SD; Son BH; Ahn SH; Kim SB
Breast Cancer Res Treat; 2011 Jul; 128(1):171-7. PubMed ID: 21519835
[TBL] [Abstract][Full Text] [Related]
3. Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.
Kingston B; Kayhanian H; Brooks C; Cox N; Chaabouni N; Redana S; Kalaitzaki E; Smith I; O'Brien M; Johnston S; Parton M; Noble J; Stanway S; Ring A; Turner N; Okines A
Breast; 2017 Dec; 36():54-59. PubMed ID: 28968585
[TBL] [Abstract][Full Text] [Related]
4. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.
Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P
Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122
[TBL] [Abstract][Full Text] [Related]
5. Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry.
Witzel I; Laakmann E; Weide R; Neunhöffer T; Park-Simon TJ; Schmidt M; Fasching PA; Hesse T; Polasik A; Mohrmann S; Würschmidt F; Schem C; Bechtner C; Würstlein R; Fehm T; Möbus V; Burchardi N; Loibl S; Müller V
Eur J Cancer; 2018 Oct; 102():1-9. PubMed ID: 30099223
[TBL] [Abstract][Full Text] [Related]
6. Analysis of survival outcomes based on molecular subtypes in breast cancer brain metastases: A single institutional cohort.
Jeon W; Jang BS; Jeon SH; Kim JH; Kim YJ; Kim SH; Kim CY; Han JH; Kim IA
Breast J; 2018 Nov; 24(6):920-926. PubMed ID: 30596408
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
[TBL] [Abstract][Full Text] [Related]
8. Limited overall survival in patients with brain metastases from triple negative breast cancer.
Morris PG; Murphy CG; Mallam D; Accordino M; Patil S; Howard J; Omuro A; Beal K; Seidman AD; Hudis CA; Fornier MN
Breast J; 2012; 18(4):345-50. PubMed ID: 22607041
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
[TBL] [Abstract][Full Text] [Related]
10. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
Heitz F; Harter P; Lueck HJ; Fissler-Eckhoff A; Lorenz-Salehi F; Scheil-Bertram S; Traut A; du Bois A
Eur J Cancer; 2009 Nov; 45(16):2792-8. PubMed ID: 19643597
[TBL] [Abstract][Full Text] [Related]
11. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
12. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
13. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.
Sperduto PW; Kased N; Roberge D; Xu Z; Shanley R; Luo X; Sneed PK; Chao ST; Weil RJ; Suh J; Bhatt A; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2111-7. PubMed ID: 21497451
[TBL] [Abstract][Full Text] [Related]
14. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N
Oncology; 2013; 84(3):135-40. PubMed ID: 23235554
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Brain Metastasis-Free Interval in Patients with Breast Cancer Brain Metastases.
Hulsbergen AFC; Lamba N; Claes A; Kavouridis VK; Lin NU; Smith TR; Verhoeff JJC; Broekman MLD
World Neurosurg; 2019 Aug; 128():e157-e164. PubMed ID: 31035019
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis.
Morikawa A; Jordan L; Rozner R; Patil S; Boire A; Pentsova E; Seidman AD
Clin Breast Cancer; 2017 Feb; 17(1):23-28. PubMed ID: 27569275
[TBL] [Abstract][Full Text] [Related]
20. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
